Find us on:


Research Type
Reported as
Publication Type
Sort By
Total: 183
Efficacy and Tolerability of Low-dose Naltrexone for Pain Relief among Neuropathic Corneal Pain Patients
Research Type Human Reported as Case Report/Series/Restrospective Study Date June 15, 2020 Authors Gabriela Dieckmann; Mehmet Cuneyt Ozmen; Ryan Engert; Pedram Hamrah Institution Tufts Medical Center Disease Neuropathic Corneal Pain
PURPOSE: Neuropathic corneal pain (NCP) is a recently described ocular pain modality resulting from nerve damage and presenting with symptoms of pain or persistent unpleasant sensations, such as dryness, burning, or light sensitivity. When symptoms do not resolve with topical anesthetics, this point to a non-ocular source of pain. Low-dose naltrexone (LDN) acts as a neuromodulator with a neuroprotective effect via inhibition of microglial activation in the central nervous system and upregulation...
Hailey-Hailey Disease Successfully Treated with Low-Dose Naltrexone
Research Type Human Reported as Case Report/Series/Restrospective Study Date May 31, 2020 Authors John Moesch, Richard Miller Institution Largo Medical Center Disease Hailey-Hailey
Hailey-Hailey disease (HHD) is an uncommon autosomal dominant disorder resulting from a mutation in the ATP2C1 gene resulting in dysfunction of the Golgi apparatus calcium-associated ATPase, thus interfering with intercellular calcium signaling. HHD presents clinically as flaccid blisters and erosions in intertriginous areas, especially the axillae and groin. The major histologic finding is acantholysis throughout the spinous layer of the epidermis, commonly referred to as a “dilapidated bric...
The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris; a randomized controlled clinical trial.
Research Type Human Reported as Clinical Trial Date May 23, 2020 Authors Vahideh Lajevardi, Fereshteh Salarvand, Maryam Ghiasi,Maryam Nasimi, Mohammad Taraz Institution Tehran University of Medical Sciences Disease Lichen Planopilaris
BACKGROUND: Lichen planopilaris (LPP) is one of the important causes of cicatricial alopecia. We aimed to evaluate the efficacy and safety of low-dose naltrexone (LDN) in the setting of a clinical trial in patients with LPP. METHODS: We included patients with LPP between 2018 and 2020. Patients were allocated to two groups. The first group received topical clobetasol plus oral low dose naltrexone (3mg) while the second received topical clobetasol plus placebo. The assessment was made for the d...
Erythromelalgia in a Patient with Mast Cell Activation Syndrome: Response to Low Dose Naltrexone
Research Type Human Reported as Case Report/Series/Restrospective Study Date May 13, 2020 Authors Anastasia O Kurta, Leonard B Weinstock, Natalie Semchyshyn Institution Saint Louis University, Specialists in Gastroenterology Disease Erythromelalgia, MCAS (mast cell activation syndrome)
Erythromelalgia is a rare condition that may be associated with a variety of underlying conditions and is often refractory to therapy. We report a case of a patient with mast cell activation syndrome who developed erythromelalgia and responded to low dose naltrexone....
Low-dose Naltrexone Therapy for Psoriasis
Research Type Human Reported as Case Report/Series/Restrospective Study Date March 21, 2020 Authors L. B. Weinstock, J. Cottel, L. Aldridge, A. Egeberg Institution Washington University School of Medicine, University of Copenhagen Disease Psoriasis
Safe, inexpensive, and convenient psoriasis therapy is desirable. Two recent case reports suggested that low-dose naltrexone is effective. Cases from our practice are presented in order to further the evidence of efficacy and safety of low-dose naltrexone in the treatment of psoriasis. Patients included 13 females, 2 males; mean age 57 years; mean psoriasis duration 16 years. Of the patients, 8 had psoriatic arthritis. In the past, 5 had completely failed and 10 had partially responded t...
Naltrexone Hydrochloride 1.5-mg and 4.5-mg Capsules
Research Type Human Reported as Review Date March 19, 2020 Authors Loyd V. Allen, Jr., PhD Institution University of Oklahoma
Pharmacist Dr. Loyd V. Allen, Jr. reviews methods of preparation, uses, packaging, labeling, stability, and quality control of 1.5mg and 4.5mg capsules of low dose naltrexone. An interesting and unexpected effect of naltrexone is its action in pain relief for different disorders. A notable aspect of naltrexone use in pain patients is that the dose is only about one-tenth of the normal dose. Since naltrexone HCl is available in 50-mg tablets, low-dose naltrexone must be compounded for patients....
Low-dose naltrexone in Hailey-Hailey disease: the importance of dosing.
Research Type Human Reported as Review Date March 11, 2020 Authors P. Acharya, M. Mathur Institution Nepal College of Medical Sciences Disease Hailey-Hailey
We read with great interest the study by Jasans-Barceló et al. where they report the response of low-dose naltrexone in 8 patients of HHD. One interesting observation we made in the article was the response of one patient to the standard higher dose (50 mg) of naltrexone. Two previous studies that used the 50mg dose in HHD patients (3 patients total) had failed to show any positive response....
Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway.
Research Type Animal Date March 11, 2020 Authors M. Ma, X. Wang, N. Liu, F. Shan, Y. Feng Institution China Medical University Disease Cancer (general), Colorectal Cancer
The incidence of colorectal cancer (CRC) is increasing annually worldwide. However, traditional chemotherapy has obvious side effects. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Therefore, the aim of this study was to explore the mechanisms underlying the inhibitory effect of LDN on CRC progression in vivo and in vitro. We found that expression of macrophage markers (F4/80, CD68) was increased in nude mice treated with LDN compared ...
Enkephalin Therapy Improves Relapsing-Remitting Multiple Sclerosis
Research Type Human Reported as Case Report/Series/Restrospective Study Date January 28, 2020 Authors Chirag L. Patel, Ian S. Zagon, Gary A. Thomas and Patricia J. McLaughlin Institution Penn State University Disease MS (Multiple Sclerosis)
Multiple sclerosis (MS) is accompanied by decreases in serum endogenous enkephalin/endorphins and alterations in inflammatory cytokines. This retrospective analysis of serum levels was conducted in 53 patients with established relapsing-remitting MS treated with the disease-modifying therapies (DMT) glatiramer acetate, dimethyl fumarate or with the biotherapeutic low dose naltrexone (LDN) to elevate enkephalins, an off-label alternative. Opioid growth factor (OGF), an inhibitory endogenous opioi...
The Lowdown on Low-Dose Naltrexone
Research Type Human Reported as Review Date January 27, 2020 Authors Nadine Shabeeb Institution University of Wisconsin Disease Psoriasis
Low-dose naltrexone (LDN) has become a hot topic in many fields of medicine, including dermatology. It has gained popularity as an alternative, off-label treatment that works by targeting inflammation. Patients may ask you about LDN as a treatment option for a variety of inflammatory skin conditions, specifically in comparison to more traditional systemic treatments. It is important for dermatologists to know what LDN is, how it works, how to prescribe it, and what side effects should be monitor...